Formal clinical evaluation of the CADD-Micro system for circadian delivery of FUDR in patients with metastatic renal cell cancer.
The CADD-Micro System (Sims Deltec, St. Paul, MN) was formally evaluated in patients with metastatic renal cell cancer, participating in a phase-III study comparing a 2-week circadian versus flat infusion of FUDR. Ten patients participated, 2 receiving five cycles of FUDR by a flat infusion, and 8 receiving 12 cycles of FUDR by circadian infusion. A total of 235 treatment days were evaluated. All patients had a Port-A-Cath in place for venous access. The patients completed a structured evaluation survey for each week of treatment regarding their interaction with the pump and an overall evaluation of the system and the patient information guide at the end of each 2-week course. Nurses from our home infusion program completed a separate evaluation. Overall patient and clinician perception of this pump was excellent. The main drawback had to do with the design of the battery compartment cover and the handling of the drug reservoir. The small size of the drug reservoir (10 mL) limits the usability of this pump to low-volume tasks.
Bjarnason
G A
GA
Toronto-Sunnybrook Regional Cancer Center, North York, Ontario, Canada.
Doyle
N
N
Sone
M
M
Beattie
K
K
Elia
J
J
Owens
B
B
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D002940:Circadian Rhythm; D004334:Drug Administration Schedule; D005069:Evaluation Studies as Topic; D005467:Floxuridine / Q000008:administration & dosage*; D006801:Humans; D007260:Infusion Pumps; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000556:secondary
D000964:Antimetabolites, Antineoplastic; D005467:Floxuridine